UNSPSC 51141559: Loreclezole

This classification denotes an anticonvulsant agent with the molecular formula C10H6Cl3N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6DJ32STZ5W, chemically known as 1h-1,2,4-triazole, 1-(2-chloro-2-(2,4-dichlorophenyl)ethenyl)-, (z)- but generally known as loreclezole, which bears US NIH Compound Identifier 3034012. European Medicines Agency schedules Loreclezole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08586MIG.

UNSPSC 51141559 Loreclezole is a Commodity code representing pharmaceutical products, but state and local governments are not soliciting loreclezole specifically under this code. Recent opportunities tagged to this code instead involve broader pharmaceutical procurement — naloxone distribution, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements — suggesting a mismatch between the code's nominal scope and actual buying activity.

The three recent opportunities span county health departments, state health and human services agencies, and cooperative purchasing alliances. Seminole County, Florida (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries and fixed-fee pricing including shipping. The Texas Health and Human Services Commission (HHS0017013, posted April 3, 2026) issued a Request for Information to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (S1070000015802, due March 26, 2026) sought manufacturers of generic and over-the-counter pharmaceuticals to supply participating state and local facilities across multiple states, including Oregon, with distribution through three authorized wholesalers and pricing weighted 75 percent on competitiveness. The code shows minimal targeted activity for loreclezole itself, and firms pursuing pharmaceutical supply contracts should expect broad RFP and cooperative purchasing structures rather than commodity-specific solicitations.